ANEST IWATA (6381) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
13 Jun, 2025Executive summary
Net sales rose 2.5% year-over-year to ¥12,484 million, driven by strong sales in Europe and the Americas, especially in coating equipment, but operating profit declined 19.9% to ¥1,017 million due to increased SG&A expenses and higher labor costs overseas.
Net income attributable to owners of parent fell 23.5% year-over-year to ¥1,052 million.
Comprehensive income increased 25.1% year-over-year to ¥2,534 million, driven by foreign currency translation gains.
The global economy remained uncertain due to inflation and geopolitical risks, with Japan seeing weak capital investment and stagnant business sentiment.
Financial highlights
Gross profit increased 2.7% year-over-year to ¥5,706 million, with a stable gross margin of 45.7%.
SG&A expenses rose 9.4% year-over-year, mainly from higher labor costs in Europe, the Americas, and China.
Ordinary profit decreased 14.8% year-over-year to ¥1,704 million, impacted by lower foreign exchange gains.
Basic earnings per share dropped to ¥26.52 from ¥34.01 year-over-year.
Dividend per share for the quarter was ¥27.00, up from ¥22.00 in the prior year.
Outlook and guidance
Full-year forecasts remain unchanged: net sales ¥58,000 million (+8.6%), operating profit ¥6,800 million (+10.1%), net income ¥4,950 million (+0.4%).
Overseas sales, especially in Europe, the US, and India, are expected to drive growth; moderate recovery anticipated in China.
Annual dividend forecast is ¥50.00 per share.
Risks include China's economic slowdown, global monetary policies, currency trends, and geopolitical factors.
Latest events from ANEST IWATA
- Profits and sales fell, but financial stability and full-year guidance were maintained.6381
Q3 202610 Feb 2026 - Sales and profit fell, but FX gains and cash flow stability kept guidance unchanged.6381
Q2 202628 Nov 2025 - Q1 sales and profits declined, comprehensive income turned negative, but guidance is unchanged.6381
Q1 20268 Aug 2025 - Sales rose but profits fell on margin and forex pressures; outlook and dividend steady.6381
Q2 202413 Jun 2025 - Sales up, profits down; FY2025 targets higher sales, lower earnings, and a dividend increase.6381
Q4 20256 Jun 2025 - Profit outlook cut as China lags and costs rise, but investment and R&D remain on track.6381
Q3 20255 Jun 2025